Lecture Demonstrations Clause Samples

Lecture Demonstrations. (1) A Lecture/Demonstration shall count as one-half (1/2) performance service providing that the total elapsed time including travel but excluding Rest Time between demonstrations does not exceed four (4) hours, and providing that each Lecture/Demonstration does not exceed fifty (50) minutes in length. If Lecture/Demonstration exceeds fifty (50) minutes in length, overtime shall apply in one- half (1/2) hour increments. There shall be not more than three (3) Lecture/Demonstrations in any one day, each being separated by not less than one and one-half (1-1/2) hours if travel is involved and by no less than one-half (1/2) hour if no travel is involved. A Back-to-Back Lecture/Demonstration shall consist of two Lecture/ Demonstrations, each not to exceed fifty (50) minutes in length, performed in the same location for two different audiences within a two and one-half (2 1/2) hour period with an interval of not less than twenty-five (25) consecutive minutes between. A Back to Back Lecture/Demonstration is equivalent to one (1) full performance. (2) In the event that a Lecture/Demonstration is scheduled on the same day as a regular performance, the provisions of this Agreement relative to a two-performance day will apply. No ARTIST may appear in more than one Lecture/Demonstration on a performance day. With the exception of back-to-back Lecture/Demonstrations, should an ARTIST appear in more than one (1) Lecture/Demonstration on ARTIST performance day, said ARTIST will be paid not less than one-sixth (1/6) ARTIST'S weekly salary. (3) On Lecture/Demonstration days, the performance and travel shall be counted in actual time. (a) When LECTURE/DEMONSTRATIONS require travel, all travel shall be provided by EMPLOYER. The called time shall include the period from departure to the venue until return from the venue. A thirty-minute break shall be given to the ARTIST upon return. If a LECTURE/ DEMONSTRATION encompasses the COMPANY lunch break, the ARTISTS performing the LECTURE/DEMONSTRATION shall be given an additional 15 minutes either by a 15-minute break during the period of travel or by extending the rest period for 15 minutes. For example, if the travel and performance total 3 hours, and the COMPANY is rehearsing a six- ho ur day, the ARTISTS may be called for three additional 3 hours of rehearsal, provided all other regulations regarding work day procedures (rest period, span., etc.) are followed. (b) When no travel is required for LECTURE/DEMONSTRATIONS, the follo...
View SourceView Similar (2)
Lecture Demonstrations. ‌ a. A Lecture Demonstration shall count as one half (½) of a Performance provided the Lecture Demonstration does not exceed fifty (50) minutes. A Lecture Demonstration which exceeds fifty (50) minutes shall count as one (1) Performance. A Performance constitutes three (3) hours of Artistic Activity. b. There shall be at least a one half (½) hour Rest Time between Lecture Demonstrations unless the Lecture Demonstrations are identical and occur at the same venue in which case there shall be at least a twenty (20) minute Rest time between such Lecture Demonstrations. There shall be at least a one half (½) hour Rest Time between a Lecture Demonstration and a subsequent rehearsal. c. Travel to or between Lecture Demonstrations shall not exceed one (1) hour. Travel time constitutes Artistic Activity.
View Source
Lecture Demonstrations a) Definition 1) An activity not to exceed fifty (50) minutes in duration for the purpose of conveying the art form to a new audience consisting of but not limited to students, teachers, and other interested persons. 2) A Lecture/Demonstration shall count as one-half (1/2) performance service providing that the total elapsed time including travel but excluding Rest Time between demonstrations does not exceed four (4) hours, and providing that each Lecture/Demonstration does not exceed fifty (50) minutes in length. If Lecture/Demonstration exceeds fifty (50) minutes in length, overtime shall apply in one-half (1/2) hour increments. There shall be not more than three (3) Lecture/Demonstrations in any one day, each being separated by not less than one and one-half (1-1/2) hours if travel is involved and by no less than one-half (1/2) hour if no travel is involved. b) Back-to-Back Lecture/Demonstration A Back-to-Back Lecture/Demonstration consists of two Lecture/Demonstrations, each not to exceed fifty (50) minutes in length, performed in the same location for two, different audiences within a two and one-half (2-1/2) hour period with an interval of not less than twenty-five (25) consecutive minutes between. It is equivalent to one (1) full performance service.
View Source

Related to Lecture Demonstrations

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Research Reports Distributor acknowledges that Dealer may prepare research reports relating to the Fund that are not to be used for marketing purposes (“Research Reports”). Distributor hereby authorizes Dealer to use the name of the Fund, Distributor and BREDS in Research Reports.

  • Product Development (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting, Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period, then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential Information. (b) From time to time, each party may request the other party to participate in joint projects to develop Improvements. Neither party is obligated to participate in such projects, and in each **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. instance, each party’s decision whether to participate will be made in such party’s sole discretion. If both parties mutually agree to participate in such a project (a “Program”), the parties will promptly prepare a mutually agreeable written development agreement specifying the development activities to be performed by and the research and development tasks assigned to each party (the “Development Agreement”). All allocation of Intellectual Property rights with respect to any Program will be set forth in writing in the Development Agreement. (c) In the absence of a Development Agreement, (i) BioForm and Supplier shall retain joint ownership of Intellectual Property rights in which there is joint inventorship by BioForm (or its Affiliates) and Supplier, as determined in accordance with United States patent law, with Supplier’s rights in such joint ownership being subject to the license rights of BioForm under this Agreement, (ii) any Intellectual Property rights related to the Company Products, Enhancements, and Improvements that are created solely by employees or consultants of Supplier during the Term shall be considered to be Intellectual Property rights of Supplier, subject to the license rights of BioForm under this Agreement, and (iii) any Intellectual Property rights related to the Company Products and Improvements that are created solely by employees or consultants of BioForm or any of its Affiliates during the Term shall be considered to be Intellectual Property rights of BioForm. BioForm hereby grants to Supplier a perpetual, royalty free, world-wide, nonexclusive license to Supplier under such Blocking Intellectual Property to make, use, and sell such Intellectual Property outside the Field. “Blocking Intellectual Property” for the purposes of Section 8.4(c)(iii) shall mean Intellectual Property necessary for Supplier to make, use, or sell SA Product.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • SERVICE MONITORING, ANALYSES AND ORACLE SOFTWARE 11.1 We continuously monitor the Services to facilitate Oracle’s operation of the Services; to help resolve Your service requests; to detect and address threats to the functionality, security, integrity, and availability of the Services as well as any content, data, or applications in the Services; and to detect and address illegal acts or violations of the Acceptable Use Policy. Oracle monitoring tools do not collect or store any of Your Content residing in the Services, except as needed for such purposes. Oracle does not monitor, and does not address issues with, non-Oracle software provided by You or any of Your Users that is stored in, or run on or through, the Services. Information collected by Oracle monitoring tools (excluding Your Content) may also be used to assist in managing Oracle’s product and service portfolio, to help Oracle address deficiencies in its product and service offerings, and for license management purposes. 11.2 We may (i) compile statistical and other information related to the performance, operation and use of the Services, and (ii) use data from the Services in aggregated form for security and operations management, to create statistical analyses, and for research and development purposes (clauses i and ii are collectively referred to as “Service Analyses”). We may make Service Analyses publicly available; however, Service Analyses will not incorporate Your Content, Personal Data or Confidential Information in a form that could serve to identify You or any individual. We retain all intellectual property rights in Service Analyses. 11.3 We may provide You with the ability to obtain certain Oracle Software (as defined below) for use with the Services. If we provide Oracle Software to You and do not specify separate terms for such software, then such Oracle Software is provided as part of the Services and You have the non-exclusive, worldwide, limited right to use such Oracle Software, subject to the terms of this Agreement and Your order (except for separately licensed elements of the Oracle Software, which separately licensed elements are governed by the applicable separate terms), solely to facilitate Your use of the Services. You may allow Your Users to use the Oracle Software for this purpose, and You are responsible for their compliance with the license terms. Your right to use any Oracle Software will terminate upon the earlier of our notice (by web posting or otherwise) or the end of the Services associated with the Oracle Software. Notwithstanding the foregoing, if Oracle Software is licensed to You under separate terms, then Your use of such software is governed by the separate terms. Your right to use any part of the Oracle Software that is licensed under the separate terms is not restricted in any way by this Agreement.